Milrinone: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
Ostermayer (talk | contribs) (Text replacement - " pts" to " patients") |
||
| Line 45: | Line 45: | ||
==Notes== | ==Notes== | ||
*Can use as alternative to dobutamine in | *Can use as alternative to dobutamine in patients with cardiogenic shock and on b-blockers | ||
*Causes pulmonary vasodilation, may be good choice in | *Causes pulmonary vasodilation, may be good choice in patients with RV failure | ||
*↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR | *↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR | ||
*Use with caution in pt with renal failure and hypovolemia | *Use with caution in pt with renal failure and hypovolemia | ||
Revision as of 16:49, 21 June 2016
General
- Type: Vasopressors
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Dosing
- Normal renal function:
0.25 - 0.75 mcg/kg/min
- Creatinine clearance < 50mL/min, reduce infusion rate
Rate of Titration
- Q2H; slower titration rate if renal insufficiency
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Tachyarrhythmias
- Hypotension
- Myocardial ischemia
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Primary Receptor
- PDE-3 inhibitor
Relative Effects
- ↑HR
- ↑↑↑SV
- ↓SVR
Notes
- Can use as alternative to dobutamine in patients with cardiogenic shock and on b-blockers
- Causes pulmonary vasodilation, may be good choice in patients with RV failure
- ↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR
- Use with caution in pt with renal failure and hypovolemia
Indication
low cardiac output states due to impaired myocardial contractility